anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Children and youth with Autism Spectrum Disorder (ASD) often present with co-morbid impairments in self-regulation (e.g., difficulty managing their emotions) resulting in unhelpful regulatory approaches such as disruptive compulsive, aggressive and self-injurious behaviour. There is an urgent need to establish novel, precise and effective interventions that promote self-regulation and reduce disruptive behaviours. This project will collect pilot data on the effects of repetitive TMS in reducing disruptive behaviours in youth with ASD, in order to inform the design of a follow-up full-scale clinical trial. Youth with ASD who experience clinically significant difficulties with self-regulation and disruptive behaviour will be recruited. Participants will be randomized to rTMS or sham rTMS for 3 weeks. The overall feasibility of the trial will be assessed. The effect of rTMS on the brain mechanisms of self-regulation and clinical improvement in disruptive behaviours will also be measured. Neurophysiological outcomes, including changes in regional brain network activity for inhibition of behaviour, will be explored.
Subjects will 12 acupuncture treatments over 6 weeks; treatment sessions occur twice a week. A total of 12 acupuncture needles will be inserted bilaterally at two leg points and four back points. Needles are manually inserted through a standard guide tube contained within a fitted sheath and the basal ring secured to the skin by double-sided tape. The needles remain in place for 25 minutes and are manually stimulated twice during each treatment.
Chewable tablets including essences of five-colour fruits and vegetables comprise an essence layer of red fruits and vegetables, an essence layer of yellow fruits and vegetables, an essence layer of green fruits and vegetables, an essence layer of white fruits and vegetables and an essence layer of black fruits and vegetables. The essence layer of red fruits and vegetables comprises natural red grape powder, cherry powder, cherry tomato powder, apple extract, hawthorn extract. The essence layer of yellow fruits and vegetables comprises natural seabuckthorn fruit powder, fragrant citrus fruit powder, soybean powder, sweet corn powder, β-carotene. The essence layer of green fruits and vegetables comprises natural Chinese gooseberry powder, broccoli extract, cactus extract, mung bean extract. The essence layer of white fruits and vegetables comprises white fungus extract, ginkgo seed extract, lily extract, lotus seed powder. The essence layer of black fruits and vegetables comprises natural mulberry fruit powder, blackcurrant powder, black sesame powder, black fungus extract, seatangle extract, mushroom extract. The preparative methods of the said tablets include: weighing the five-colour fruits and vegetables respectively, sieving through 60-80 mesh, adding fructose and mannitol, mixing homogeneously, tableting respectively, packaging the five-colour tablets into a kit; or weighing the five-colour fruits and vegetables respectively, sieving through 60-80 mesh, adding fructose and mannitol, mixing homogeneously, pressing the mixture into a multilayer tablet. The said chewable tablets can balance nutrition and strengthen functions of five internal organs of human bodies.
FIELD: medicine. SUBSTANCE: cooking pot is filled with water and heated, then a mixer is turned on and molten bee wax is added. A second cooking pot is loaded with fat base, vegetable oil, cocoa oil, heated and mixed. The fat mass is transferred from the second pot into the first one, and mixed. The emulsified mass is pumped into a cooling pot and cooled. Then aromatizer is added and the mass is mixed. The cooled cream is settled and packed. EFFECT: higher biologically-active effect on face skin.
Atherosclerosis, the leading cause of death and disability in the world, is considered an inflammatory disease with a complex etiology. The immune system has a prominent role in the formation, development and destabilization of atherosclerotic plaques. A whole range of identified cytokines have been shown to play a part in atherogenesis, some with proatherogenic properties while others having antiatherogenic properties. With increasing evidence for the significant role of inflammation and the cytokines involved together with the Th1/Th2 imbalance in atherosclerosis and its progression to Coronary artery diseases (CADs), the control of cytokine production may become potential therapeutic targets and modulation of the Th1/Th2 balance may provide a new pharmacological tool to treat this disease. Vitamin A (VA) or VA-like analogs known as retinoids, are potent hormonal modifiers of type 1 or type 2 responses but a definitive description of their mechanism(s) of action is lacking. high level dietary vitamin A enhances Th2 cytokine production and IgA responses, and is likely to decrease Th1 cytokine production. Retinoic acid inhibits IL 12 production in activated macrophages, and RA pretreatment of macrophages reduces IFNγ production and increases IL4 production in antigen primed CD4 T cells. Supplemental treatment with vitamin A or retinoic acid (RA) decreases IFNγ and increases IL5, IL10, and IL4 production. Thus, vitamin A deficiency biases the immune response in a Th1 direction, whereas high level dietary vitamin A may bias the response in a Th2 direction.
FIELD: pharmacy. SUBSTANCE: bergmycin - the combined preparation, it is prepared from Bergenia pacifica (lat.) rhizome active components and levomycetin added. New preparation has, %: tannides 55-56; starch and sugar 21-26; levomycetin 5-10, and water 5-8. Preparation is an amorphous light-brown powder, shows strong astringent property, low-insoluble in water and alcohol, stored in sealed pots. Preparation normalizes gastroenteric tract function, its effect develops in 20-30 min and continues for 3-6 h. Bergmycin shows favorable action of blood components, enhances animal organism resistance. Preparation is used at infected and noninfected gastroenteric disorders, thermic burns, suppurative-necrotic processes in animals and poultries. Curative effect of bergmycin against diarrhea in young animals is 10-20% above as compared their active components, its antimicrobial activity is increased by 4-fold, it is harmless for animals and human. EFFECT: enhanced effectiveness of preparation.
BACKGROUND: Sepsis-associated encephalopathy (SAE) develops in 30-70% of hospitalized patients with sepsis. In intensive care units (ICUs), propofol is often administered to ensure an appropriate level of sedation in mechanically ventilated patients. Ferroptosis is a newly identified mode of cellular death characterized by the peroxidation of membrane lipids and excessive iron. This study was conducted to explore the interplay between propofol, sepsis, and ferroptosis.
METHODS: An acute systemic inflammatory model was constructed via the intraperitoneal administration of lipopolysaccharide (LPS). Nissl and Fluoro-Jade C (FJC) staining were employed to display neuronal damage and degeneration. Western blotting and immunofluorescence (IF) staining of Bax and Bcl-2 were used to confirm the neural apoptosis. QPCR of cytokines and DHE staining were used to indicate neuroinflammation. To validate ferroptosis, we assessed the content of malondialdehyde (MDA), GSH, and tissue iron, accompanied by transcription level of CHAC1, PTGS2 and GPX4. Additionally, we examined the content of acyl-CoA synthetase long-chain family member 4 (ACSL4), xCT (SLC7A11, solute carrier family 7 member 11), and glutathione peroxidase 4 (GPX4). The IF staining of Iba1-labeled microglia and GFAP-marked astrocytes were used to measure the gliosis. Erastin was pre-pretreated to confirm the anti-ferroptotic capability of propofol. ML385 was preconditioned to explore the role of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in propofol-repressed ferroptosis.
RESULTS: Propofol dose-dependently inhibited the decrease of Nissl-positive neurons and the increase of FJC-stained neurons in septic hippocampus and cortex. Neural cytokines, oxidative stress, apoptosis and gliosis were reduced by propofol. Propofol repressed the level of MDA, iron, CHAC1, PTGS2, ACLS4 and restored the content of GSH, GPX4, xCT, Nrf2 and HO-1, thus inhibiting sepsis-induced ferroptosis. All protections from propofol could be reversed by eratsin and ML385 pretreatment.
CONCLUSION: Propofol protected against sepsis-induced brain damage, neuroinflammation, neuronal apoptosis and gliosis through the activation of the Nrf2/HO-1 axis to combat ferroptosis.
A composition for killing warble fly larvae by oral administration to infested animals, comprises an organo-tin compound, viz. a saturated or unsaturated aliphatic carboxylic or dicarboxylic acid salt of a dialkyltin, e.g. di-n-butyltin dilaurate, together with phenothiazine and hexachloro-ethane preferably in the proportions of 1:20:10 by weight.  An inert suspending and/or wetting agent, e.g. bentonite and an excipient, e.g. lactose may also be incorporated.
PROBLEM TO BE SOLVED: To provide an environment where communications are smoothly exchanged among medical employees in an electronic chart system. SOLUTION: This system is provided with an editing information setting means 120 which sets editing information including retrieval conditions or the like for diagnosis and treatment information, a communicating means 121 which transmits and receives the editing information and an editing information processing means 122 which performs prescribed processing on the basis of the editing information. Further, the editing information includes a message such as sound and a dynamic image. Meanwhile, it is provided with a connection information recording means which manages a communication state such as an unread state and prevents a communication omission among medical employees. Also, the means 121 simultaneously transmits to plural communication destinations.  It transmits and receives only edition information such as retrieval condition of diagnosis and treatment information necessary to communication. Thus, the data is prevented from being made a mass due to useless added files, the deterioration of response is prevented and also the operability of a receiving side is improved.
AIMS: This study aimed to investigate the effects of Umbelliferone (UMB) on the inflammation underlying alveolar bone resorption in mouse periodontitis.
METHODS: Male Swiss mice subjected to a ligature of molars were grouped as non-treated (NT), received UMB (15, 45, or 135 mg/kg) or saline daily for 7 days, respectively, and were compared with naïve mice as control. Gingival tissues were evaluated by myeloperoxidase (MPO) activity and interleukin-1β level by ELISA. The bone resorption was directly assessed on the region between the cement-enamel junction and the alveolar bone crest. Microscopically, histomorphometry of the furcation region, immunofluorescence for nuclear factor-kappa B (NF-ĸB), and immunohistochemistry for tartrate-resistant acid phosphatase (TRAP), and cathepsin K (CTSK) were performed. Systemically, body mass variation and leukogram were analyzed.
RESULTS: Periodontitis significantly increased MPO activity, interleukin-1β level, and NF-ĸB+ immunofluorescence, and induced severe alveolar bone and furcation resorptions, besides increased TRAP+ and CTSK+ cells compared with naïve. UMB significantly prevented the inflammation by reducing MPO activity, interleukin-1β level, and NF-ĸB+ intensity, besides reduction of resorption of alveolar bone and furcation area, and TRAP+ and CTSK+ cells compared with the NT group. Periodontitis or UMB treatment did not affect the animals systemically.
CONCLUSION: UMB improved periodontitis by reducing inflammation and bone markers.
The present disclosure provides a printable composition. The printable composition includes a polymer, a polymerizable component, a temporary solvent, a photoinitiator, and optionally an inhibitor. The present disclosure also provides an article including an integral blend of a thermoset polymer and a second polymer different from the thermoset polymer. Further, the present disclosure provides a method of making an article. The method includes (i) providing a printable composition; (ii) selectively curing the printable composition to form a gelled article; and (iii) removing at least a portion of the temporary solvent from the gelled article. The method may optionally include (iv) curing unpolymerized polymerizable component remaining before or after step (iii). Also, methods are provided, including receiving, by a manufacturing device having one or more processors, a digital object comprising data specifying a plurality of layers of an article, the article including: an integral blend of 8 to 50 wt. %, inclusive, of a thermoset polymer and 30 to 90 wt. %, inclusive, of a second polymer different from the thermoset polymer, wherein the weight percent is based on the total weight of the article; and generating, with the manufacturing device by an additive manufacturing process, the article based on the digital object. A system is provided, including a display that displays a 3D model of an article; and one or more processors that, in response to the 3D model selected by a user, cause a 3D printer to create a physical object of an article.
Cardiomyopathy, defined as symptomatic and asymptomatic decline in left ventricular ejection fraction (LVEF), can occur with COTELLIC. The safety of COTELLIC has not been established in patients with a baseline LVEF that is either below institutional lower limit of normal (LLN) or below 50%. 

In Trial 1, patients were assessed for decreases in LVEF by echocardiograms or MUGA at baseline, Week 5, Week 17, Week 29, Week 43, and then every 4 to 6 months thereafter while receiving treatment. Grade 2 or 3 decrease in LVEF occurred in 26% of patients receiving COTELLIC with vemurafenib and 19% of patients receiving vemurafenib. The median time to first onset of LVEF decrease was 4 months (range 23 days to 13 months). Of the patients with decreased LVEF, 22% had dose interruption and/or reduction and 14% required permanent discontinuation. Decreased LVEF resolved to above the LLN or within 10% of baseline in 62% of patients receiving COTELLIC with a median time to resolution of 3 months (range: 4 days to 12 months). 

In Trial 2, in patients with histiocytic neoplasms, 8% of patients experienced grade 2 ejection fraction decreased and 12% experienced grade 3-4 events. The median time to first onset of LVEF decrease was 29 days (range 22 days to 114 days). Of the patients with decreased LVEF, all had dose interruption and/or reduction and none required permanent discontinuation. Decreased LVEF resolved to above the LLN or within 10% of baseline in 60% of patients receiving COTELLIC with a median time to resolution of 31 days (range: 13 days to 126 days).

Evaluate LVEF prior to initiation, 1 month after initiation, and every 3 months thereafter until discontinuation of COTELLIC. Manage events of left ventricular dysfunction through treatment interruption, reduction, or discontinuation [see Dosage and Administration (2.3)]. In patients restarting COTELLIC after a dose reduction or interruption, evaluate LVEF at approximately 2 weeks, 4 weeks, 10 weeks, and 16 weeks, and then as clinically indicated.
The invention relates to a Chinese medicinal composition for treating eczema and a preparation thereof. The eczema is common inflammatory dermatosis caused by various internal and external factors of epidermis and dermis superficial layers. At present, in western medicine treatment, antihistamine medicaments for oral administration and corticoid medicaments are used mostly to inhibit temporarily, the treatment effect is poor, the eczema is not treated radically and the side effect is large. Thus, the eczema is treated mainly by Chinese medicaments. The Chinese medicinal composition of the invention is prepared from Chinese patent medicaments of lightyellow sophora root, astragalus, large-headed atractylodes rhizome, rhizoma smilacis glabrae and the like which are used for clearing heat and drying damp and taken as main materials, and cortex moutan for clearing heat and cooling blood and activating blood and resolving stasis, dictamnus bark for clearing away heat and toxic materials and expelling wind-damp, red paeony root for clearing heat and cooling blood and promoting blood circulation and removing blood stasis and raw liquoric root for tonifying the spleen and qi and clearing away heat and toxic materials, and the medicaments are processed into an oral administration preparation for invigorating the spleen and promoting diuresis and promoting blood circulation and removing blood stasis. The decades of clinical application and experiments prove that the Chinese medicinal composition has the excellent effect on the treatment of the eczema and the effect of relieving constipation, and has the effects of improving gastrointestinal tracts obviously during the administration of patients.
Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
There is no known antidote for EPIVIR. One case of an adult ingesting 6 g of EPIVIR was reported; there were no clinical signs or symptoms noted and hematologic tests remained normal. Two cases of pediatric overdose were reported in Study ACTG300. One case involved a single dose of 7 mg/kg of EPIVIR; the second case involved use of 5 mg/kg of EPIVIR twice daily for 30 days. There were no clinical signs or symptoms noted in either case. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event. If overdose occurs, the patient should be monitored, and standard supportive treatment applied as required.
The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
Patients were enrolled at the time of biopsy with histologic and /or molecular signs of rejection. Donor-derived cell-free DNA (dd-cf DNA) were measured at the time of biopsy before centre standard of care treatment and then at weeks 1, 2 and 3 after biopsy.
The present invention relates to yolk lecithin used for injection and a preparing method thereof, which obtains useful substances from an animal raw material containing protein and fat. The present invention particularly relates to the yolk lecithin used for injection and a preparing method thereof, wherein the yolk lecithin used for injection is obtained from yolk powder. The method uses the yolk powder as the raw material. After the granules of which the water content is not higher than 3.0% and supercritical carbon dioxide are used for carrying out the static extraction for 0.5 to 1.5 hours, the continuous circulating extraction is carried out for 1.5 to 3.5 hours, and two-stage separation is simultaneously carried out. The yolk powder of which the yolk oil and the cholesterol are removed is dissolved and concentrated by alcohol, and is washed by acetone to be dissolved by the alcohol. The lecithin is precipitated out by adding water. The yolk lecithin used for injection is obtained by drying in a freezing mode. The present invention has the advantages of simple technical devices, easy operation, great reduction of organic solvent dosage, environmental pollution reduction, low producing cost, stable product quality and low solvent residual quantity.
Adjuvant-free recombinant influenza candidate vaccine based on the Nucleoprotein (NP) of the influenza virus. One single administration intramuscularly of a 300μg dose on Day 1.
The invention discloses a protease activated peptide and application thereof in preparing a medicament for preventing and/or treating myocardial ischemia/reperfusion injury, and relates to the technical field of biological medicines. The amino acid sequence of the protease activation peptide is shown as SEQ ID NO. 1. The invention discovers that the protease activation peptide can reduce the apoptosis after myocardial ischemia/reperfusion and myocardial cell hypoxia/reoxygenation and reduce the oxidative stress level. In addition, the protease activation peptide can also improve the activity of a proteasome, improve the mitochondrial function and state of myocardial cells after hypoxia/reoxygenation, increase the mitochondrial membrane potential, increase ATP generation, reduce membrane permeation and transformation holes and reduce mitochondrial division. Therefore, the protease activation peptide can be used for preparing medicines for preventing and/or treating myocardial ischemia/reperfusion injury.
In a method and computer for determining an imaging parameter for an imaging procedure, a patient-specific imaging value for imaging an image data set is provided to a computer. An imaging parameter is determined in the computer by applying a trained imaging rule to the patient-specific imaging value. The trained imaging rule is based on a number of training data sets, wherein the training data sets each includes at least one patient-specific training imaging value and at least one training imaging parameter and at least one training quality evaluation. The complex influences of the patient-specific imaging values and the imaging parameters on the result of imaging can be quantified thereby. Allocation of the training quality evaluation by individual operators or specific groups of operators makes it possible to adjust the image recording parameters flexibly and individually. The imaging parameter can be determined such that the result of imaging is individually adjusted to an operator.